GENFIT Spotlights MASH Diagnostics with Key Opinion Leader Event
Event summary
- GENFIT to host virtual KOL event on September 9, 2026, featuring Dr. Vlad Ratziu to discuss MASH diagnostics.
- Labcorp's NASHnext®, based on GENFIT’s NIS4®, gained reimbursement eligibility under the Clinical Laboratory Fee Schedule on August 10, 2026.
- GENFIT’s NIS4® and NIS2+® technologies are included in European and U.S. clinical guidelines for MASH diagnostics.
- Company to discuss commercial opportunities and revenue potential of its diagnostic technologies during the event.
The big picture
GENFIT’s focus on MASH diagnostics comes at a critical time as treatment options for the disease expand rapidly. The company’s non-invasive diagnostic technologies, NIS4® and NIS2+®, are positioned to capture a significant share of the growing market for MASH diagnostics, supported by their inclusion in clinical guidelines and recent reimbursement milestones. The virtual KOL event underscores GENFIT’s strategic push to highlight the clinical utility and commercial potential of its diagnostic franchise, aiming to solidify its leadership in the space.
What we're watching
- Reimbursement Impact
- Whether the recent reimbursement eligibility for NASHnext® will accelerate adoption and drive revenue growth for GENFIT.
- Commercial Strategy
- How GENFIT plans to leverage its diagnostic technologies to expand partnerships and broaden patient access.
- Market Dynamics
- The pace at which non-invasive diagnostic technologies like NIS4® and NIS2+® will replace liver biopsies as the standard for MASH diagnosis.
Related topics